- Home
- XFOR vs PBYI Comparison
XFOR vs PBYI Comparison
Compare XFOR & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XFOR
- PBYI
- Stock Information
- Founded
- XFOR 2014
- PBYI 2010
- Country
- XFOR United States
- PBYI United States
- Employees
- XFOR N/A
- PBYI N/A
- Industry
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- XFOR Health Care
- PBYI Health Care
- Exchange
- XFOR Nasdaq
- PBYI Nasdaq
- Market Cap
- XFOR 320.0M
- PBYI 263.4M
- IPO Year
- XFOR N/A
- PBYI N/A
- Fundamental
- Price
- XFOR $3.52
- PBYI $5.09
- Analyst Decision
- XFOR Strong Buy
- PBYI Strong Buy
- Analyst Count
- XFOR 3
- PBYI 1
- Target Price
- XFOR $34.67
- PBYI $7.00
- AVG Volume (30 Days)
- XFOR 1.7M
- PBYI 622.4K
- Earning Date
- XFOR 11-05-2025
- PBYI 11-06-2025
- Dividend Yield
- XFOR N/A
- PBYI N/A
- EPS Growth
- XFOR N/A
- PBYI 59.87
- EPS
- XFOR N/A
- PBYI 0.74
- Revenue
- XFOR $33,979,000.00
- PBYI $211,995,000.00
- Revenue This Year
- XFOR $1,307.51
- PBYI N/A
- Revenue Next Year
- XFOR N/A
- PBYI N/A
- P/E Ratio
- XFOR N/A
- PBYI $6.97
- Revenue Growth
- XFOR 2925.74
- PBYI N/A
- 52 Week Low
- XFOR $1.35
- PBYI $2.32
- 52 Week High
- XFOR $26.83
- PBYI $6.12
- Technical
- Relative Strength Index (RSI)
- XFOR 49.67
- PBYI 50.68
- Support Level
- XFOR $3.26
- PBYI $4.80
- Resistance Level
- XFOR $3.86
- PBYI $6.12
- Average True Range (ATR)
- XFOR 0.32
- PBYI 0.41
- MACD
- XFOR -0.02
- PBYI -0.03
- Stochastic Oscillator
- XFOR 31.21
- PBYI 37.86
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.